

# PROVIDER QUICK POINTS

## PROVIDER INFORMATION



June 4, 2015

### **Update to Buprenorphine and Buprenorphine/Naloxone (Bunavail™/Suboxone®/Zubsolv®) Prior Authorization and Quantity Limit Criteria**

Effective June 15, 2015, if a prior authorization (PA) renewal request is denied for products in this category, a **one-time 30 day PA** will be granted. The purpose of this one-time 30 day PA is to allow providers adequate time to develop and implement a suitable transition plan for their patients either to: successfully meet requirements of the program, or discontinue therapy. In the former case, another PA request will be required for the renewal evaluation.

Please note: Drug quantity and strength limits should not exceed the program's established limits for the requested product.

#### **Additional information**

The current PA and quantity limit criteria for Buprenorphine and Buprenorphine/Naloxone can be accessed using the Blue Cross and Blue Shield of Minnesota provider link.

- Access [providers.bluecrossmn.com](http://providers.bluecrossmn.com)
- Under Tools And Resources, select Medical policy, then acknowledge the Acceptance statement
- Select View All Active Policies
- Select Pharmacy Utilization Management Programs

#### **Questions?**

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.